Background and Purpose-Although secondary medical prevention strategies in patients with stroke are well established, only sparse data exist regarding their effectiveness in routine care. We examined the effectiveness in a nationwide, population-based follow-up study. 
T he efficacy of secondary medical prophylaxis after stroke has been investigated in a number of large randomized clinical trials (RCTs). 1, 2 Although RCT findings on efficacy cannot automatically be expected to represent effectiveness in clinical settings, few studies have examined the effectiveness of secondary stroke prevention. [3] [4] [5] [6] [7] [8] Current stroke guidelines recommend that lifelong medical prophylaxis including antithrombotic, antihypertensive, and lipid-lowering therapy be considered for all patients with ischemic stroke regardless of age and sex. 1, 2 However, a number of studies have demonstrated an insufficient implementation of secondary prophylaxis in patients with stroke. 9 -12 Evidence of the effectiveness of secondary medical prophylaxis in patients with ischemic stroke would potentially provide a strong argument supporting further efforts to ensure compliance with RCT-based clinical guidelines. We therefore examined the effectiveness of secondary medical prophylaxis after ischemic stroke in a nationwide, population-based follow-up study.
Methods

Setting and Design
This study was based on data covering the entire Danish population (approximately 5.5 million). The National Health Service provides tax-supported health care to all residents, including free access to general practitioners and hospitals; the National Health Service also refunds a variable proportion of prescription medication costs. The Danish Civil Registration System maintains electronic records of changes in the vital status of all citizens. 13 Each record carries a unique 10-digit civil registration number that is used in all Danish registries and enables unambiguous linkage among these registries.
Study Population
We used the Danish National Indicator Project (DNIP) to identify all patients admitted with acute stroke between January 1, 2003, and June 30, 2006 (nϭ36 075) . The DNIP is a nationwide initiative to monitor and improve the quality of care for specific diseases by monitoring fulfillment of quality criteria related to the structure, process, and outcome of health care. 14 Participation in the project is mandatory for all departments treating patients with acute stroke, and all patients (Ն18 years) admitted with acute stroke are eligible for inclusion. We excluded 4870 patients who died in the hospital or within 30 days after hospital discharge, 2548 patients with hemorrhagic stroke, and 45 patients with missing information regarding admission and/or discharge dates. We restricted the study population to the first stroke event registered during the study period among patients who were residents of Denmark and therefore available for follow-up (nϭ28 612).
Medical Prophylaxis
Data on prescriptions filled after discharge were obtained from the Medical Register of the Danish Medicines Agency, which contains data on all prescription drugs dispensed at all pharmacies. We traced all prescriptions for antiplatelets, oral anticoagulants, angiotensinconverting enzyme inhibitors, ATII antagonists, ␤-blockers, calcium blockers, thiazide diuretics, and statins that were filled for patients with stroke from hospital discharge to date of death or December 31, 2007, whichever came first. These drugs are available by prescription only, except for low-dose acetylsalicylic acid. However, lowdose acetylsalicylic acid is generally prescribed by physicians rather than bought over the counter, because chronic users and pensioners can be reimbursed for prescription drugs. Antiplatelets included low-dose acetylsalicylic acid, clopidogrel, and dipyridamole.
Patient Characteristics
The following data were collected at the time of hospital admission: sex, marital status, type of residence, Scandinavian Stroke Scale score (a measure of stroke severity 15 ), history of stroke or acute myocardial infarction (AMI), previous and/or current atrial fibrillation, hypertension, diabetes mellitus or intermittent claudication, smoking habits, and alcohol intake. Information on the quality of in-hospital care was obtained from the DNIP and included data on early admission to a specialized stroke unit, early administration of antiplatelet or anticoagulant therapy, early examination with CT or MRI, early assessment by a physiotherapist and an occupational therapist, and assessment of nutritional risk. We computed the percentage of relevant processes of care received for each patient as a measure of the quality of in-hospital stroke care. We also computed the Charlson comorbidity index score for each patient based on all discharge diagnoses recorded before hospitalization for stroke. Data on previous hospitalizations were obtained from the National Registry of Patients, which contains data on all discharges from all nonpsychiatric hospitals in Denmark since 1977. 16 The Charlson comorbidity index covers 19 major disease categories. 17 We defined 3 levels of comorbidity: 0 points ("low"), 1 to 2 points ("moderate"), and Ͼ2 points ("high"). Former stroke, AMI, diabetes, and a history of dementia were excluded from the index and were instead included as individual covariates due to the well-established prognostic role of these conditions. Information on socioeconomic status the year before hospital admission was obtained from the Integrated Database for Labor Market Research. Socioeconomic status was based on the annual income and source of income for each person and was collected from tax returns and other public registries.
Outcomes
The study outcomes included death and hospitalization with AMI and recurrent stroke (ischemic stroke, hemorrhagic stroke, and stroke without specification). The outcomes were considered both individually and as a combined outcome. Data on the outcomes were obtained from the Civil Registration System, the National Registry of Patients, and the DNIP.
Statistical Analysis
We first assessed the cumulative risk of death, AMI, and recurrent stroke. Death was considered a competing risk in relation to AMI and recurrent stroke. Patients were followed from the date of discharge until the date of outcome (death, AMI, or recurrent stroke) or December 31, 2007, whichever came first for each patient. Second, we used Cox proportional hazards regression with the Efron approximation to handle tied survival times to compute hazard ratios (HRs) for the combined outcome as well as death, AMI, and recurrent stroke separately according to the use of secondary medical prophylaxis with no treatment as reference. Drug uses were included as time-dependent variables to eliminate the risk of immortal time bias with the prescription fill date as the start date and 90-day duration for each prescription. 18 Multiple imputation was used to impute missing values for former stroke, former AMI, diabetes, atrial fibrillation, hypertension, intermittent claudication, Scandinavian Stroke Scale score, smoking, alcohol consumption, type of residence at hospitalization, socioeconomic status, and civil status. We generated 5 imputed data sets, and the HRs were then averaged across the 5 imputations correcting for between-and within-imputation variation. 19 In addition to all measured covariates, we included the event indicator and the NelsonAalen estimator of the cumulative hazard to the survival time in the imputation model. 20 All analyses were also stratified for age and sex (men or women Յ65 years, men or women 65-80 years, and men or women Ͼ80 years).
Finally, propensity scores were calculated for all patients for use in a propensity score stratified analysis according to the quartiles of the propensity score (0.0 -0.18, 0.18 -0.28, 0.28 -0.49, and 0.49 -1.00). The propensity score reflected the chance of filling prescriptions for a combination of antiplatelet, antihypertensive, and statin therapies within 180 days after hospital discharge for each patient; this score was computed based on a logistic regression analysis including the following prognostic factors: sex, age, Charlson score, diabetes, atrial fibrillation, former AMI, hypertension, former stroke, intermittent claudication, stroke severity, smoking, alcohol, type of residence, civil status, in-hospital antithrombotic therapy, in-hospital anticoagulant therapy, and socioeconomic status. This analysis was restricted to patients surviving at least 180 days after hospital discharge and performed to examine effectiveness among patients with a similar chance of starting secondary prophylactic treatment. We analyzed data using Stata 11 (StataCorp LP, Collage Station, TX) and SAS 9.1.3 (SAS Institute Inc, Cary, NC).
Figure.
Cumulative risk with CIs of death, acute myocardial infarction, and recurrent stroke after hospital discharge among 28 612 patients with ischemic stroke.
Results
Supplemental Table I (http://stroke.ahajournals.org) shows the characteristics of the 28 612 included patients. During the follow-up study period (mean, 2.5 years), we recorded 7462 deaths, 837 AMIs, and 2658 recurrent stroke events in the entire study population. The cumulative risk after a maximum of 5 years of follow-up for death, AMI, or recurrent stroke was 37.6% (95% CI, 36.0%-39.3%), 3.9% (95% CI, 3.5%-4.4%), and 11.7% (95% CI, 10.9%-12.5%), respectively ( Figure) .
We calculated the crude and adjusted HRs for various outcomes according to the use of secondary medical prophylaxis (Table) . For the combined outcome, the overall adjusted HRs ranged from 0.44 to 0.94 for treatment compared with no treatment for the 7 examined drug groups with the lowest risk estimates found for oral anticoagulants, statins, and antiplatelets.
The overall adjusted mortality HRs ranged from 0.38 to 0.86 for treatment compared with no treatment for the 7 examined drug groups. Although antiplatelet therapy was associated with a lower risk of death in all age and sex groups, the HRs were lowest in the youngest patients; the adjusted HRs for men and women Յ65 years were 0. ‡Patients with known atrial fibrillation during hospitalization and no contraindications against oral anticoagulant therapy. §Angiotensin-converting enzyme inhibitors/ATII antagonists, ␤-blockers, calcium blockers, and thiazide diuretics alone or in combination.
were detected for the remaining drugs when the analyses were stratified according to age and sex (data not shown). The overall adjusted HRs for AMI ranged from 0.77 to 1.41 for treatment compared with no treatment for the examined drugs (Table) . Although not all risk estimates reached statistical significance, all adjusted HRs were Ͻ1.00, except for antihypertensives (any type), ␤-blockers, and calcium blockers (Table) . The overall adjusted HRs for recurrent stroke ranged from 0.58 to 1.13 for treatment compared with no treatment for various drugs (Table) ; use of oral anticoagulants (adjusted HR, 0.58; 95% CI, 0.47-0.73) and statins (adjusted HR, 0.86; 95% CI, 0.79 -0.93) was associated with a lower risk of recurrent stroke. In contrast, use of any type of antihypertensive (adjusted HR, 1.13; 95% CI, 1.04 -1.24), ␤-blockers (adjusted HR, 1.13; 95% CI, 1.02-1.24), or thiazide diuretics (adjusted HR, 1.12; 95% CI, 1.01-1.25) was associated with an increased risk of recurrent stroke. We found no substantial differences in the analyses on AMI and recurrent stroke when stratifying according to age and sex (data not shown).
The results of the overall analyses were in general confirmed when stratifying the patients according to the propensity score of filling prescriptions for a combination of antiplatelet, antihypertensive, and statin therapy within 180 days after hospital discharge (Supplemental Table II ). When analyzing the risk of death, we found the lowest HRs among the patients most likely to receive combination therapy, whereas no systematic difference between the propensity score strata were found in the analyses on AMI and recurrent stroke.
Discussion
In this nationwide, population-based follow-up study, use of secondary medical prophylaxis was associated with a lower risk of an adverse clinical outcome (death, AMI, or recurrent stroke) among patients with ischemic stroke treated in routine clinical settings.
This study was strengthened by its prospective, populationbased design with complete long-term follow-up. Furthermore, our analyses were based on a large cohort with detailed information on all individuals. Immortal time bias, which is a well-recognized source of potential bias in observational studies on drug effects, was handled by including the use of drugs as time-dependent covariables in the statistical analyses as recommended in the pharmacoepidemiological literature. 18 The main limitation is the observational nature of the study design, which makes the study susceptible to confounding. Different approaches were used to minimize the possible risk of confounding (eg, analyses were restricted to patients without known contraindications and adjustments were made for a wide range of covariates); however, we cannot exclude the possibility that our results remain influenced by confounding factors. This is illustrated by the somewhat surprising finding of a higher risk of AMI among users of ␤-blockers and calcium blockers and a higher or neutral risk of recurrent stroke among users of antiplatelets, ␤-blockers, and thiazide diuretics. These findings are not in line with findings from RCTs and may possibly reflect unaccounted or residual confounding; for example, we did not have access to detailed physiological data, including blood pressure and blood lipid levels and could therefore not take into account that the patients with the highest blood pressure most likely had the highest chance of being prescribed blood pressure-lowering treatment and at the same time had the highest risk of an adverse outcome. In contrast to the somewhat inconsistent findings on AMI and recurrent stroke, all examined drug classes were associated with a lower mortality rate, which is in partial accordance with recent meta-analyses of RCTs on secondary medical prophylaxis among other patient groups with vascular disease. 21, 22 The apparent discrepancy between some of the findings on death, AMI, and recurrent stroke may at least partly reflect that some fatal cases of myocardial infarction and recurrent stroke were not registered as such in our study but rather as a death because we only included myocardial infarctions and recurrent stroke episodes diagnosed in relation to a hospital admission. Patients with AMI and stroke dying before hospital admission or otherwise undiagnosed cases were therefore not counted as AMI or stroke in the analyses. The use of data collected during routine clinical work represents another possible limitation because this may have potentially affected the accuracy of the study. However, participation in the DNIP is mandatory for all departments treating patients with acute stroke in Denmark, and a systematic effort has been made to ensure the validity of the DNIP. 14 Specifically, regular structured audits are conducted nationally, regionally, and locally and include validation of the completeness of patient registration against county hospital discharge registries. We used prescription data as an indicator of drug use, but we had no information on actual patient compliance (whether the patient used all of the prescribed drugs). This lack of information could potentially introduce a misclassification into the study. However, the data are likely to provide a good reflection of actual drug use, because we only included data on prescriptions that had been filled and because the patients were only partly reimbursed.
Currently there are few investigations into the effectiveness of medical prophylactic treatment in relation to stroke, and the number of studies on secondary medical prophylaxis is even lower. Many of these previous studies are small, have incomplete follow-up, or lack detailed information on patient prognostic factors; some of these studies use inclusion criteria or study populations that could reduce their external validity. One recent study, which investigated the effectiveness of secondary drug prevention as a pooled analysis of antihypertensives, lipid-lowering drugs and antithrombotics, found this treatment to be associated with a significant reduction in mortality risk. 7 This is in accordance with our findings in which use of antithrombotics, antihypertensives, and statins was associated with an apparently independently reduced risk of all-cause mortality. The effectiveness of antiplatelet therapy in secondary prophylaxis after stroke has also been investigated in 3 recent Chinese publications. [3] [4] [5] The first 2 studies reported that antiplatelet therapy was associated with a lower risk of all-cause death, recurrent cerebrovascular events, and any further vascular events after ischemic stroke. 3, 4 Similarly, we found antiplatelet therapy to be associated with lower mortality, whereas use of antiplatelets was not associated with a lower risk of AMI or recurrent stroke (Table) . The third study 5 demonstrated that antiplatelet therapy was associated with a reduced risk of death within 1 year after stroke in women (adjusted HR. 0.55; 95% CI. 0.37-0.83 with no treatment as reference), whereas this association was not observed for men (estimate not presented in the article). We could not confirm a sex-related difference in the effectiveness of antiplatelet therapy in the present study. However, in accordance with a meta-analysis based on 12 RCTs, 23 antiplatelet therapy also appeared to be relatively less effective with increasing patient age in our patient population.
The effectiveness of oral anticoagulant therapy has primarily been examined in relation to primary stroke prophylaxis. 24 -29 All of these studies reported that oral anticoagulant therapy among patients with atrial fibrillation was associated with a lower risk of ischemic stroke, an observation in accordance with our detection of a lower risk of recurrent stroke events after use of oral anticoagulants (Table) . We also found the use of oral anticoagulants to be associated with a lower risk of all-cause death and AMI in our population, although our finding was not statistically significant for AMI (Table) . Also, although a previous meta-analysis reported the efficacy of oral anticoagulants to be unchanged with increasing age, 23 we found that oral anticoagulants appeared to be more effective with increasing age, especially among women Ͼ80 years of age.
The effectiveness of antihypertensive therapy has been examined in 2 recent studies in which antihypertensive treatment was associated with a lower mortality rate. 5, 8 This observation is in accordance with our findings (Table) . Two other studies detected an association between the use of nonthiazide antihypertensives and an increased risk of first stroke and stroke severity. 30, 31 We found ␤-blocker therapy and thiazide diuretic therapy to be associated with a higher risk of recurrent stroke events; furthermore, use of nonthiazide antihypertensives was associated with a higher risk of AMI in our study (Table) . Interestingly, recent work from Rothwell and colleagues based on RCT data demonstrate that a high-dose calcium channel blocker reduces systolic blood pressure variability compared with other blood pressurelowering agents, in particular ␤-blockers, and that treatment with calcium channel blockers may therefore be particularly effective in the prevention of stroke. 32, 33 In our study, the adjusted HRs of the combined end point (0.83; 95% CI, 0.78 -0.88) as well as recurrent stroke (1.00; 95% CI, 0.90 -1.12) associated with use of calcium channel blockers also appeared to be lower than the corresponding HRs for the use of ␤-blockers (combined end point, 0.94; 95% CI, 0.89 -0.99; recurrent stroke, 1.13; 95% CI, 1.02-1.24).
Two recent studies focused on secondary prophylaxis with statins in patients with stroke. 4, 6 Both of these studies found that statin therapy was associated with a lower risk of new vascular events in patients admitted with stroke, although none of these associations were statistically significant. We also found that statin therapy was associated with a statistically significant lower risk of mortality, AMI, and recurrent stroke events (Table) .
In conclusion, our investigation revealed that the use of secondary medical prophylaxis was associated with a lower risk of an adverse clinical outcome in patients with ischemic stroke. For antiplatelets, the effectiveness appeared to vary by age but not by sex, and for oral anticoagulants, it appeared to vary by age, in particular among women. These observational data support the hypothesis that the efficacy of secondary medical prophylaxis in patients with stroke documented in RCTs overall appears to translate well into everyday clinical practice.
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